The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Xiapex collagenase Clostridium histolyticum | Swedish Orphan Biovitrum AB | Dupuytren Contracture | 🇪🇺 EU 2011-02-28 | Order → |
| Entacapone Teva entacapone Generic | Teva Pharma B.V. | Parkinson Disease | 🇪🇺 EU 2011-02-18 | Order → |
| Fluenz influenza vaccine (live attenuated, nasal) Additional monitoring | MedImmune LLC | Influenza, Human; Immunization | 🇪🇺 EU 2011-01-27 | Order → |
| Docetaxel Teva Pharma docetaxel Generic | Teva Pharma B.V. | Carcinoma, Non-Small-Cell Lung; Breast Neoplasms; Prostatic Neoplasms | 🇪🇺 EU 2011-01-21 | Order → |
| Iasibon ibandronic acid Generic | Pharmathen S.A. | Hypercalcemia; Fractures, Bone; Neoplasm Metastasis; Breast Neoplasms | 🇪🇺 EU 2011-01-21 | Order → |
| Potactasol topotecan Generic | Actavis Group PTC ehf | Uterine Cervical Neoplasms; Small Cell Lung Carcinoma | 🇪🇺 EU 2011-01-06 | Order → |
| Brilique ticagrelor | AstraZeneca AB | Peripheral Vascular Diseases; Acute Coronary Syndrome | 🇪🇺 EU 2010-12-03 | Order → |
| Possia ticagrelor | AstraZeneca AB | Peripheral Vascular Diseases; Acute Coronary Syndrome | 🇪🇺 EU 2010-12-03 | Order → |
| Prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) | Novartis Vaccines and Diagnostics S.r.l. | Influenza, Human; Immunization; Disease Outbreaks | 🇪🇺 EU 2010-11-29 | Order → |
| Aflunov zoonotic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) | Seqirus S.r.l. | Influenza, Human; Immunization; Disease Outbreaks | 🇪🇺 EU 2010-11-28 | Order → |
| Leflunomide ratiopharm leflunomide Generic | Ratiopharm GmbH | Arthritis, Rheumatoid | 🇪🇺 EU 2010-11-28 | Order → |
| Clopidogrel HCS clopidogrel Generic | HCS bvba | Peripheral Vascular Diseases; Acute Coronary Syndrome; Myocardial Infarction; Stroke | 🇪🇺 EU 2010-10-28 | Order → |
| Clopidogrel Teva Generics B.V. clopidogrel Generic | Teva Pharma B.V. | Peripheral Vascular Diseases; Acute Coronary Syndrome; Myocardial Infarction; Stroke | 🇪🇺 EU 2010-10-28 | Order → |
| Ruconest conestat alfa | Pharming Group N.V. | Angioedemas, Hereditary | 🇪🇺 EU 2010-10-28 | Order → |
| Myclausen mycophenolate mofetil Generic | Passauer Pharma GmbH | Graft Rejection | 🇪🇺 EU 2010-10-07 | Order → |
| Twynsta telmisartan;amlodipine | Boehringer Ingelheim International GmbH | Hypertension | 🇪🇺 EU 2010-10-07 | Order → |
| Telmisartan Actavis telmisartan Generic | Actavis Group PTC ehf | Hypertension | 🇪🇺 EU 2010-09-29 | Order → |
| Ibandronic Acid Teva ibandronic acid Generic | Teva Pharma B.V. | Breast Neoplasms; Neoplasm Metastasis; Fractures, Bone; Osteoporosis, Postmenopausal | 🇪🇺 EU 2010-09-17 | Order → |
| Rapiscan regadenoson | GE Healthcare AS | Myocardial Perfusion Imaging | 🇪🇺 EU 2010-09-06 | Order → |
| Brinavess vernakalant hydrochloride | Advanz Pharma Limited | Atrial Fibrillation | 🇪🇺 EU 2010-09-01 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.